within Pharmacolibrary.Drugs.ATC.J;

model J01RA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0003,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01RA12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ciprofloxacin and ornidazole is a fixed-dose combination antibacterial and antiprotozoal drug. Ciprofloxacin, a fluoroquinolone, acts by inhibiting bacterial DNA gyrase; ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa. This combination is used primarily for the treatment of mixed bacterial and protozoal infections, especially in gastrointestinal infections such as diarrhea and dysentery. The fixed-dose combination is widely used in several countries but is not approved by the US FDA or EMA as a combination product.</p><h4>Pharmacokinetics</h4><p>Estimated typical adult pharmacokinetics after combined oral administration, based on published data for individual components (ciprofloxacin and ornidazole) in healthy adults; no compartmental PK for the fixed combination was identified.</p><h4>References</h4><ol><li><p>Boeckh, M, et al., &amp; Krasemann, C (1990). Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. <i>Antimicrobial agents and chemotherapy</i> 34(12) 2407–2414. DOI:<a href=\"https://doi.org/10.1128/AAC.34.12.2407\">10.1128/AAC.34.12.2407</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2088195/\">https://pubmed.ncbi.nlm.nih.gov/2088195</a></p></li><li><p>El-Kimary, EI, et al., &amp; Abdel Moneim, MM (2018). Sensitive inexpensive chromatographic determination of an antimicrobial combination in human plasma and its pharmacokinetic application. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1097-1098 94–100. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2018.09.008\">10.1016/j.jchromb.2018.09.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30218919/\">https://pubmed.ncbi.nlm.nih.gov/30218919</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01RA12;
